Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Dermatology
    • Newer Biologics safer...

    Newer Biologics safer than Methotrexate for treatment of psoriasis, JAMA Dermatology

    Written by Deepanjana Sarkar Published On 2019-05-14T19:28:15+05:30  |  Updated On 14 May 2019 7:28 PM IST
    Newer Biologics safer than Methotrexate for treatment of psoriasis, JAMA Dermatology

    Newer systemic biologics have a decreased rate of serious infection in comparison to methotrexate in psoriasis treatment, finds a new study publshed in the journal JAMA Dermatology.


    Psoriasis is a common, chronic inflammatory disease of the skin caused by the overactive immune system. The introduction of biologics has brought a revolution in the treatment standards of psoriasis. Systemic medications available in the United States and approved by the US FDA for moderate-to-severe and severe psoriasis include older agents such as acitretin and methotrexate, as well as novel agents including the biologics and apremilast, a small molecule inhibitor of phosphodiesterase.


    Despite their efficacy, adherence to biologics and systemic medications for psoriasis is low, with infection having been shown to be a leading cause of discontinuation.


    Psoriasis patients are at a higher risk of developing a serious infection. The study used 2 large electronic databases to compare the risk of serious infection in patients with psoriasis who were new users of 6 systemic medications (acitretin, adalimumab, apremilast, etanercept, infliximab, and ustekinumab) to new users of methotrexate using a large national cohort of commercially insured US adults.


    The researchers analyzed the occurrence of primary outcome identified as serious infection requiring hospitalization, using previously validated ICD-9-CM codes with an overall positive predictive value of 90.2%. Serious infection was defined as a primary inpatient diagnosis code for pneumonia, meningitis/encephalitis, bacteremia/sepsis, cellulitis/soft-tissue infection, endocarditis, pyelonephritis, and septic arthritis/osteoarthritis. We also conducted secondary analyses examining each type of serious infection separately.


    The researchers identified 31 595 patients in claims data from Optum Clinformatics Data Mart and 76,112 patients in Truven MarketScan from 2003 through 2015 who were new users of acitretin, adalimumab, apremilast, etanercept, infliximab, methotrexate, and ustekinumab.


    The researchers found a significantly decreased rate of serious infection with apremilast, etanercept, and ustekinumab compared with methotrexate. In both claims databases, investigators observed a lower risk of overall serious infections among patients receiving apremilast (hazard ratio, etanercept, and ustekinumab compared to methotrexate. There was not a difference in rate of overall serious infections among patients using acitretin, adalimumab, and infliximab compared with methotrexate.


    To know more about the study, please click on the link

    doi:10.1001/jamadermatol.2019.1121
    biologicscellulitisEncephalitisEndocarditisetanerceptFDAimmune systeminfliximabJAMAJAMA DermatologymeningitisMethotrexateosteoarthritispneumoniapsoriasisPsoriasis medicationpyelonephritissepsisseptic arthritissoft-tissue infectionustekinumab

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Deepanjana Sarkar
    Deepanjana Sarkar
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok